Literature DB >> 17476621

The prevalence of fibromyalgia in Japanese workers.

K Toda1.   

Abstract

OBJECTIVE: To estimate the point prevalence of fibromyalgia (FM) among hospital workers and to make a list of the reported FM prevalence using the classification criteria of the American College of Rheumatology (ACR) for FM.
METHODS: Three hundred and forty-three females and 196 males were surveyed using the 1990 ACR classification criteria of FM. The subjects were staff workers and non-staff workers (such as floor sweepers and personnel of pharmaceutical companies) who worked in medical institutions.
RESULTS: One hundred and six of the 343 females (30.9%) and 34 of the 196 males (17.3%) had complained of widespread pain for at least 3 months. All subjects who had complained of widespread pain for at least 3 months were examined by one experienced physician. Seven of the 343 females (2.04%) and one of the 196 males (0.51%) met the ACR criteria for FM. All of these eight subjects had seen a physician after the occurrence of widespread pain. Four of the eight subjects with FM had seen a physician in the past year. Only one subject had been diagnosed with FM before this study.
CONCLUSION: The advantage of this study was the extremely low dropout rate. FM is a common musculoskeletal disorder among Japanese adult workers, especially among female workers.

Entities:  

Mesh:

Year:  2007        PMID: 17476621     DOI: 10.1080/03009740600907949

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  12 in total

1.  Prevalence of chronic widespread pain and fibromyalgia syndrome: a Korean hospital-based study.

Authors:  Cheolhwan Kim; Hyejin Kim; Jongkwan Kim
Journal:  Rheumatol Int       Date:  2011-11-06       Impact factor: 2.631

Review 2.  Worldwide epidemiology of fibromyalgia.

Authors:  Luiz Paulo Queiroz
Journal:  Curr Pain Headache Rep       Date:  2013-08

Review 3.  Prevalence of fibromyalgia in general population and patients, a systematic review and meta-analysis.

Authors:  Fatemeh Heidari; Mahdi Afshari; Mahmood Moosazadeh
Journal:  Rheumatol Int       Date:  2017-04-26       Impact factor: 2.631

4.  A fibromyalgia patient with traumatic cerebrospinal fluid leak: a case report.

Authors:  K Toda; E Moriyama; S Ishikawa
Journal:  Clin Rheumatol       Date:  2008-05-24       Impact factor: 2.980

5.  Weather sensitivity associated with quality of life in patients with fibromyalgia.

Authors:  Kazuhiro Hayashi; Kenji Miki; Noriyuki Hayashi; Ryota Hashimoto; Masao Yukioka
Journal:  BMC Rheumatol       Date:  2021-05-10

6.  Humanistic and economic burden of fibromyalgia in Japan.

Authors:  Lulu K Lee; Nozomi Ebata; Patrick Hlavacek; Marco DiBonaventura; Joseph C Cappelleri; Alesia Sadosky
Journal:  J Pain Res       Date:  2016-11-04       Impact factor: 3.133

7.  Increased risk of a suicide event in patients with primary fibromyalgia and in fibromyalgia patients with concomitant comorbidities: A nationwide population-based cohort study.

Authors:  Chen-Chia Lan; Chun-Hung Tseng; Jiunn-Horng Chen; Joung-Liang Lan; Yu-Chiao Wang; Gregory J Tsay; Chung-Yi Hsu
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

8.  Comparing common reasons for inpatient and outpatient visits between commercially-insured duloxetine or pregabalin initiators with fibromyalgia.

Authors:  Yang Zhao; Peter Sun; Mark Bernauer
Journal:  J Pain Res       Date:  2012-10-31       Impact factor: 3.133

9.  Increased Risk of Coronary Heart Disease in Patients with Primary Fibromyalgia and Those with Concomitant Comorbidity-A Taiwanese Population-Based Cohort Study.

Authors:  Chia-Hsien Su; Jiunn-Horng Chen; Joung-Liang Lan; Yu-Chiao Wang; Chun-Hung Tseng; Chung-Yi Hsu; Lichi Huang
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

10.  Real-world comparison of health care utilization between duloxetine and pregabalin initiators with fibromyalgia.

Authors:  X Peng; P Sun; D Novick; J Andrews; S Sun
Journal:  J Pain Res       Date:  2014-01-09       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.